UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/690,184	10/21/2003	Timothy J. Foster	P06335US05/BAS	8504

881 7590 01/09/2006

STITES & HARBISON PLLC
1199 NORTH FAIRFAX STREET
SUITE 900
ALEXANDRIA, VA 22314

EXAMINER	
ZEMAN, ROBERT A	
ART UNIT	**PAPER NUMBER**
1645	

DATE MAILED: 01/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/690,184	FOSTER ET AL.	
	Examiner	Art Unit	
	Robert A. Zeman	1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *18 October 2005*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-9,14 and 16-22* is/are pending in the application.

4a) Of the above claim(s) *1-9 and 18-22* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *14,16 and 17* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

The amendment and response filed on 10-18-2005 are acknowledged. Claims 14 and 16 have been amended. Claims 10-13 and 15 have been canceled. Claims 1-9 and 18-22 remain withdrawn from consideration as being drawn to non-elected inventions. Claims 14 and 16-17 are currently under examination.

Priority

Applicant's claim for priority under 35 U.S.C. 120 is deemed perfected in light of the amendment to the specification filed on 10-18-2005.

Claim Rejections Withdrawn

The provisional rejection of claims 10, 13-14 and 17 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 14, 18 and 22 of copending Application No. 10/378,674 is withdrawn in light of the amendment to claims 14 and 17 and the cancellation of claims 10 and 13. The amended claims now recite specific sequences that differ from those recited in the claims of the copending application.

The rejection of claims 10-17 are rejected under 35 U.S.C. 102(e) as being anticipated by Douchette-Stamm et al. (U.S. Patent 6,380,370 – IDS) is withdrawn in light of the amendment to claims 14 and 16 and the cancellation of claims 10-13 and 15.

As outlined previously, Douchette-Stamm et al. disclose a polypeptide from *Staphylococcus epidermidis* (see SEQ ID NO:5314) with 99.9% sequence homology to the SdrG

protein of the instant application (SEQ ID NO:10). Douchette-Stamm et al. further disclose antibodies that specifically bind to said polypeptide (see column 9, lines 8-22). Finally, Douchette-Stamm et al. disclose the use of said antibodies in methods "...for preventing or treating disease caused by certain bacteria", including *S. epidermidis*..." (i.e. bacterial infection)[see column 10, lines 42-50]. The amended claims, however, require that said antibodies bind to a specific portion of the SdrG protein (i.e. amino acid residues 51-598 of SEQ ID NO:10 which is encoded by nucleic acid residues 151-1794 of SEQ ID NO:7). Based on the disclosure of Douchette-Stamm et al., one cannot conclude that their antibodies would necessarily bind to the claimed amino acid sequences. Consequently, Douchette-Stamm et al. no longer anticipate all the limitations of the instant claims.

The rejection of claim 15 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the phrase "amino acids 32 to 961 of SEQ ID NO:10" is withdrawn. Cancellation of said claim has rendered the rejection moot.

Claim Objections

Claim 17 is objected to because of the following informalities: said claim contains an obvious typographical error. "Inhbiti" should read "inhibit". Appropriate correction is required.

Claim Rejections Maintained

35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 14 and 16-17 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is maintained essentially for the reasons set forth in the previous Office action in the rejection of claims 10-17. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The cancellation of claims 10-13 and 15 renders the rejection of said claims moot.

Applicant argues:

1. Since Applicant's have disclosed a specific antigen, they have met the requirements for written description as set forth in Example 16 of The Written Description Guidelines.

2. The specification discloses the isolation of protein antigens (including SdrG) and antibodies which bind to said protein antigens. Moreover, the specification discloses the application of said antibodies for the purpose of treating or preventing infection.

Applicant's arguments have been fully considered and deemed non-persuasive.

The rejected claims are drawn to methods of utilizing antibodies that bind to fragments of the *Staphylococcus epidermidis* SdrG protein (i.e. amino acid residues 51-598 of SEQ ID NO:10

and the fragment encoded by nucleic acid residues 151-1794 of SEQ ID NO:7) to treat or prevent coagulase-negative staphylococcal infections upon their administration to a subject.

With regard to Point 1, Applicant is correct that the specification meets the written description requirement with regard to antibodies that bind the SdrG protein. However, the instant claims, as amended, require the claimed antibodies not only be able to bind the recited portion of SdrG, but they must also elicit a therapeutic or prophylactic immune response to coagulase-negative staphylococci. Since the specification does not adequately describe antibodies with both properties, the specification does not meet the written description requirement with regard to antibodies that **both** bind to the recited portion of SdrG **and** elicit a therapeutic or prophylactic immune response to coagulase-negative staphylococci (see below).

With regard to Point 2, while the specification discloses prophetically the therapeutic and prophylactic use of anti-SdrG antibodies, the specification is silent with regard to antibodies that bind the claimed portions of SdrG and elicit and therapeutic or prophylactic effect against coagulase-negative staphylococci.

The claims encompass, in part, a vast genus of antibodies that are capable of binding to the recited portions of the *Staphylococcus epidermidis* SdrG protein. Within this large genus, the claims further encompass a subgenus of antibodies that must have efficacy to treat or prevent coagulase-negative staphylococcal infections by inhibiting fibrinogen binding. There is no basis in the specification, as filed, or the art at the time of the invention to distinguish the members of this subgenus from the members of the larger genus.

To fulfill the written description requirements set forth under 35 USC § 112, first paragraph, the specification must describe at least a substantial number of the members of the

claimed genus, or alternatively describe a representative member of the claimed genus, which shares a particularly defining feature common to at least a substantial number of the members of the claimed genus, which would enable the skilled artisan to immediately recognize and distinguish its members from others, so as to reasonably convey to the skilled artisan that Applicant has possession the claimed invention. To adequately describe the genus of antibodies that are encompassed by the rejected claims one must describe not just those determinants that would elicit an immune response to the SdrG polypeptide (i.e. that produce antibodies that bind to the claimed SdrG fragment) but which determinants would give rise to antibodies that would have therapeutic and/or prophylactic efficacy against coagulase-negative staphylococcal infections since a given determinant can induce antibodies that bind to the SdrG fragment but lack any therapeutic and/or prophylactic efficacy.

The specification does not describe with any degree of specificity a single member of the genus of epitopes of SdrG to which the members of the claimed genus of antibodies must bind, wherein said antibodies can effectively treat or prevent coagulase-negative staphylococcal infections by inhibiting fibronectin binding such that the specification might reasonably convey to the skilled artisan that Applicant had possession of the claimed invention at the time the application was filed.

Moreover, the specification does not disclose distinguishing and identifying features of a representative number of members of the genus of antibodies to which the claims are drawn, such as a correlation between the structure of the immunoepitope its recited function (to induce/bind antibodies with therapeutic and/or prophylactic efficacy against coagulase-negative staphylococcal infections), so that the skilled artisan could immediately envision, or recognize at

least a substantial number of members of the claimed genus of antibodies. Additionally, the specification fails to disclose which amino acid residues are essential to the function of the immunoepitope or which amino acids might be replaced so that the resultant immunoepitope retains the activity of its parent, or by which other amino acids the essential amino acids might be replaced so that the resultant immunoepitope retains the activity of its parent. Therefore, since the specification fails to adequately describe at least a substantial number of members of the genus of immunoepitopes on which the claims are based; the specification fails to adequately describe at least a substantial number of members of the claimed genus of antibodies that bind to the claimed *Staphylococcus epidermidis* SdrG fragments **and** have therapeutic and/or prophylactic efficacy against coagulase-negative staphylococcal infections by inhibiting fibronectin binding.

MPEP § 2163.02 states, "[a]n objective standard for determining compliance with the written description requirement is, 'does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed' ". The courts have decided:

> The purpose of the "written description" requirement is broader than to merely explain how to "make and use"; the applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the "written description" inquiry, *whatever is now claimed.*

See *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Federal Circuit, 1991). Furthermore, the written description provision of 35 USC § 112 is severable from its enablement provision; and adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical*

Co. Ltd., 18 USPQ2d 1016.

The Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, paragraph 1, ``Written Description'' Requirement (66 FR 1099-1111, January 5, 2001) state, "[p]ossession may be shown in a variety of ways including description of an actual reduction to practice, or by showing the invention was 'ready for patenting' such as by disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention" (*Id.* at 1104). Moreover, because the claims encompass a genus of variant species, an adequate written description of the claimed invention must include sufficient description of at least a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics sufficient to show that Applicant was in possession of the claimed genus. However, factual evidence of an actual reduction to practice has not been disclosed by Applicant in the specification; nor has Applicant shown the invention was "ready for patenting" by disclosure of drawings or structural chemical formulas that show that the invention was complete; nor has Applicant described distinguishing identifying characteristics sufficient to show that Applicant were in possession of the claimed invention at the time the application was filed.

The *Guidelines* further state, "[f]or inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species *cannot* be achieved by disclosing only one species within the genus" (Id. at 1106); accordingly, it follows that an adequate written description of a genus cannot be achieved in the absence of a disclosure of at least one species within the genus. As evidenced by Greenspan et al. (*Nature Biotechnology* 7: 936-937, 1999),

defining epitopes is not as easy as it seems. Greenspan et al. recommends defining an epitope by the structural characterization of the molecular interface between the antigen and the antibody is necessary to define an "epitope" (page 937, column 2). According to Greenspan et al., an epitope will include residues that make contacts with a ligand, here the antibody, but are energetically neutral, or even destabilizing to binding. Furthermore, an epitope will not include any residue not contacted by the antibody, even though substitution of such a residue might profoundly affect binding. Accordingly, it follows that the immunoepitopes that can elicit a protective immune response to a given pathogen can only be identified empirically. Therefore, absent a detailed and particular description of a representative number, or at least a substantial number of the members of the genus of immunoepitopes, the skilled artisan could not immediately recognize or distinguish members of the claimed genus antibodies that bind to the *Staphylococcus epidermidis* SdrG protein and have therapeutic and/or prophylactic efficacy against coagulase-negative staphylococcal infections. Therefore, because the art is unpredictable, in accordance with the *Guidelines*, the description of immunoepitopes (antigenic determinants) is not deemed representative of the genus of antibodies to which the claims refer.

The rejection of claims 14 and 16-17 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is maintained essentially for the reasons set forth in the previous Office action in the rejection of claims 10-17. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Applicant argues:

1. The specification discloses repeatedly the use of SdrG antibodies in methods of treating or preventing staphylococcal infection and methods of preparing said antibodies (see pages 28-38, especially p 34).

2. Experimental testing in both pre-clinical and clinical setting has demonstrated that antibodies capable of binding to SdrG are capable of treating and preventing staphylococcal infections as evidenced by the "Update of Veronate" (Appendix 2).

3. Another inventive group studying antibodies to protein Fbe (asserted to be equivalent to SdrG) found that those antibodies could be used to treat or prevent infection by *S. epidermidis.*

Applicant's arguments have been fully considered and deemed non-persuasive.

With regard to Point 1, the cited portions of the specification are do not disclose (i.e. demonstrate) the claimed fragments of the SdrG protein as having efficacy in the treatment or prevention of coagulase-negative staphylococcal infection. Said portions of the specification merely prophetically refer to the use of the SdrG protein or "portions thereof" in treatment/prevention methods. The rejected claims are drawn to the prophylactic use of antibodies that bind to fragments of the SdrG protein. To be a prophylactic composition, the composition must elicit protective immunity, demonstrable by pathogen challenge experiments in a reasonable model system. The specification, as filed, does not set forth that the claimed use of the claimed antibodies provide any sort of protective immunity in any accepted model system. Applicant discloses that the antibodies to SdrG or fragments thereof "can be used to impart passive immunity, are useful for the specific detection of coagulase-negative staphylococci proteins, for the prevention a coagulase-negative infection, for the treatment of an ongoing

infection or for use as research tools" (see page 28 of specification) in a prophetic sense but fails to demonstrate said immunity/treatment in any animal system. While the skill in the art of immunology is high, to date, prediction of protective immunity (in this case passive immunity) for any given composition in any given animal is quite unpredictable. Given the lack of success in the art, the lack of working examples and the unpredictability of the generation of protective immunity, the specification, as filed, does not provide enablement for methods of inducing immunity (passive immunity) to coagulase-negative streptococci in any animal (including man), comprising administering to said animals an antibody that binds to the recited fragments of the SdrG protein.

With regard to Point 2, Appendix 2 appears to be copies of slides from a presentation. Said Appendix is deemed non-persuasive for several reasons. First, said Appendix is not properly attested and sworn to. As stated in the MPEP:

716.01(c) [R-2] Probative Value of Objective Evidence
I. **TO BE OF PROBATIVE VALUE, ANY OBJECTIVE EVIDENCE SHOULD BE SUPPORTED BY ACTUAL PROOF**
Objective evidence which must be factually supported by an appropriate affidavit or declaration to be of probative value includes evidence of unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant. See, for example, *In re De Blauwe*, 736 F.2d 699, 705, 222 USPQ 191, 196 (Fed. Cir. 1984) ("It is well settled that unexpected results must be established by factual evidence." "[A]ppellants have not presented any experimental data showing that prior heat-shrinkable articles split. Due to the absence of tests comparing appellant's heat shrinkable articles with those of the closest prior art, we conclude that appellant's assertions of unexpected results constitute mere argument."). See also *In re Lindner*, 457 F.2d 506, 508, 173 USPQ 356, 358 (CCPA 1972); *Ex parte George*, 21 USPQ2d 1058 (Bd. Pat. App. & Inter. 1991).

II. **ATTORNEY ARGUMENTS CANNOT TAKE THE PLACE OF EVIDENCE**
The arguments of counsel cannot take the place of evidence in the record. *In re Schulze*, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Examples of attorney

statements which are not evidence and which must be supported by an appropriate affidavit or declaration include statements regarding unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant.
See MPEP § 2145 generally for case law pertinent to the consideration of applicant's rebuttal arguments.

Secondly, the "evidence" presented in said Appendix is not commensurate in scope with the claimed invention. The instant claims are drawn to prophylactic/therapeutic methods utilizing antibodies that bind to specific fragments of the SdrG protein whereas the "data" presented in said Appendix is drawn to the use of Veronate® (a plasma derived, donor-selected polyclonal IVIG of unknown composition). Even if said evidence was presented in a properly executed declaration/affidavit, said evidence would not be deemed persuasive since one cannot determine whether the Veronate® composition contained antibodies that would bind to the recited fragments of the SdrG protein or whether the disclosed "immunological effects" of the Veronate® composition could be ascribed to antibodies that would bind to the recited fragments of the SdrG protein (if present). The MPEP states:

716.01(b) Nexus Requirement and Evidence of Nonobviousness
TO BE OF PROBATIVE VALUE, ANY SECONDARY EVIDENCE MUST BE RELATED TO THE CLAIMED INVENTION (NEXUS REQUIRED)
The weight attached to evidence of secondary considerations by the examiner will depend upon its relevance to the issue of obviousness and the amount and nature of the evidence. Note the great reliance apparently placed on this type of evidence by the Supreme Court in upholding the patent in *United States v. Adams*, 383 U.S. 39,148 USPQ 479 (1966).
To be given substantial weight in the determination of obviousness or nonobviousness, evidence of secondary considerations must be relevant to the subject matter as claimed, and therefore the examiner must determine whether there is a nexus between the merits of the claimed invention and the evidence of secondary considerations. *Ashland Oil, Inc. v. Delta Resins & Refractories, Inc.*, 776 F.2d 281, 305 n.42, 227 USPQ 657, 673-674 n. 42 (Fed. Cir. 1985), *cert. denied*, 475 U.S. 1017 (1986). The term "nexus" designates a factually and legally sufficient connection between the objective evidence of

nonobviousness and the claimed invention so that the evidence is of probative value in the determination of nonobviousness. *Demaco Corp. v. F. Von Langsdorff Licensing Ltd.*, 851 F.2d 1387, 7 USPQ2d 1222 (Fed. Cir.), *cert. denied*, 488 U.S. 956 (1988).

The data presented in the aforementioned Appendix does not provide said nexus and hence has no probative value.

With regard to Point 3, there is no nexus between the cited art and the instant claims as the proteins used to generate the antibodies are different and hence would contain differing immunoepitopes and would generate differing immune response. Moreover, contrary to Applicant's assertion, the cited reference does not disclose that antibodies to Fbe are effective in treating and/or preventing infection by *S. epidermidis*, said reference discloses that the Fbe protein itself is a "strong candidate for continued development of antibody-mediated therapy of prophylaxis against infection" (see page 3083). The cited reference provided no data as to the *in vivo* efficacy of antibodies to the Fbe protein. The only *in vivo* data involved the *ex vivo* opsinization of bacteria with sera prior to its injection into the test animal. The resulting data, sheds no light of the *in vivo* efficacy of antibodies to Fbe in treating established infections or preventing the development of infections. It should be noted that the cited reference only deals with a single staphylococcal species (*S. epidermidis*) while the instant claims encompass all coagulase-negative staphylococci.

As outlined previously, the specification contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention without undue experimentation.

Undue experimentation is a conclusion reached by weighing the noted factual considerations set forth below as seen in *In re* Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). A conclusion of lack of enablement means that, based on the evidence regarding each of the factors below, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.

The factors include, but are not limited to:

1. The breadth of the claims,
2. The nature of the invention,
3. The state of the prior art,
4. The level of one of ordinary skill,
5. The level of predictability in the art,
6. The amount of direction provided by the inventor,
7. The existence of working examples, and
8. The quantity of experimentation needed to make and/or use the invention based on the content of the disclosure.

Said factors as they apply to the instant claims are addressed below.

Breadth of the claims

The rejected claims are drawn to the prophylactic or therapeutic use of antibodies that bind to the recited fragments of the *Staphylococcus epidermidis* SdrG polypeptide wherein said antibodies inhibit fibrinogen binding.

Working Examples/Guidance of Specification

The specification provides no working examples demonstrating the efficacy of claimed methods. The working examples are limited to methods of identifying Sdr genes, expression of said genes and the sequencing of the resulting Sdr gene products. The specification is silent with respect to the use of specific anti-SdrG antibodies for the treatment or prevention of coagulase-negative staphylococcal infections.

State of the prior art and Unpredictability of the art

To be a prophylactic composition, the composition must elicit protective immunity, demonstrable by pathogen challenge experiments in a reasonable model system. The specification, as filed, does not set forth that the claimed use of the claimed antibodies provide any sort of protective immunity in any model system that can be extrapolated to humans or any other mammal. Applicant states that the claimed antibodies "... are useful as blocking agents to prevent or inhibit the binding of coagulase-negative staphylococci." in a prophetic sense but fails to demonstrate any therapeutic or prophylactic efficacy in any animal system. The specification is silent as to which polynucleotide/host/microorganism would be effective to prevent a given condition associated with infection by a given staphylococci species. The examples, disclosed in the instant specification, are limited to the identification Sdr genes, expression of said genes and the sequencing of the resulting Sdr gene products. While the skill in the art of immunology is high, to date, prediction of protective immunity for any given composition in any given animal is quite unpredictable. Given the lack of success in the art, the lack of working examples and the unpredictability of the generation of protective immunity, the specification, as filed, does not provide enablement for methods of preventing coagulase-negative staphylococcal infections, comprising administering to a patient antibodies to the *Staphylococci epidermidis* SdrG protein. Additionally, the specification provides no guidance as to what antibodies would be "therapeutic" for a given coagulase-negative staphylococcal infection. To be a treatment composition, said composition must provide a benefit to the subject to which it is administered. The specification, as filed, does not set forth which "antibody", if any, would provide a benefit when administered within the context of a coagulase-negative staphylococcal infection. While

the skill in the arts of medicine, pharmacology and immunology is high, to date, prediction of therapeutic efficacy for any given composition is quite unpredictable. Consequently, one of skill in the art would not be able to contemplate which "antibody" would be an effective "treatment" for a given coagulase-negative staphylococcal infection. Given the lack of success in the art, the lack of working examples and the unpredictability of therapeutic efficacy, the specification, as filed, does not provide enablement for methods of treating coagulase-negative staphylococcal infection, comprising administering an antibody that binds to the *Staphylococci epidermidis* SdrG protein.

New Grounds of Rejection

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 14 and 16-17 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

Applicant has amended claim 14 to recite "to amino acids 51-598 of SEQ ID NO:10". This phrase (i.e. recited fragment of the SdrG protein) does not appear in the specification, or original claims as filed. Applicant does not point out specific basis for this limitation in the application, and none is apparent. Therefore this limitation is new matter.

Applicant has amended claim 16 to recite "encoded by a nucleic acid having the sequence of nucleotides 151-1794 in SEQ ID NO:7". This phrase (i.e. recited fragment of the SdrG protein) does not appear in the specification, or original claims as filed. Applicant does not point out specific basis for this limitation in the application, and none is apparent. Therefore this limitation is new matter.

Applicant states that the amendments "accurately reflect the location of the A domain of the SdrG protein as clearly shown in Figure 5 of the application". However, Figure 5 does not disclose either SEQ ID NO:7 or SEQ ID NO:10. While Figure 5B seems to indicate that the A region can constitute 548 amino acids, it does not disclose which 548 amino acids constitute said A domain. Consequently, Figure 5, cannot be deemed to provide either explicit or implicit support for either of the aforementioned amendments.

Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov.

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ROBERT A. ZEMAN
PATENT EXAMINER
January 4, 2005